Endothelial Cell-Specific Molecule-1 in Critically Ill Patients With Hematologic Malignancy.

Area of Science:

• Critical Care Medicine
• Hematology
• Biomarkers

Background:

• Endothelial cell-specific molecule-1 (Endocan) is a potential biomarker in critical illness.
• Its role in critically ill hematology patients requires further investigation.
• Understanding Endocan's association with ICU resource utilization and outcomes is crucial.

Purpose of the Study:

• To evaluate the association between serum Endocan concentrations at ICU admission and ICU resource use.
• To assess the relationship between serum Endocan levels and patient outcomes in critically ill hematology patients.
• To determine if Endocan can serve as a predictive biomarker for critical care needs.

Main Methods:

• A prospective multicenter cohort study was conducted across 17 ICUs in France and Belgium.
• Seven hundred forty-four critically ill hematology patients were included, along with control groups of septic patients and healthy subjects.
• Serum Endocan concentrations were measured at ICU admission.

Main Results:

• Endocan concentrations were significantly higher in hematology patients who received prior chemotherapy.
• Elevated Endocan levels (>4.46 ng/mL) were associated with increased requirements for renal replacement therapy, mechanical ventilation, and vasopressors.
• Multivariate analysis revealed that Endocan levels were independently associated with ICU mortality (OR, 1.39; 95% CI, 1.06-1.83).

Conclusions:

• Serum Endocan concentrations at ICU admission are significantly associated with increased ICU resource utilization and mortality in critically ill hematology patients.
• Endocan demonstrates potential as a predictive biomarker for identifying patients who may benefit from early, intensive management.
• Further studies are warranted to explore the use of Endocan for risk stratification in emergency departments and hematology wards.